Substance / Medication

Oxymetazoline

Overview

Active Ingredient
oxymetazoline
RxNorm CUI
7812

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The Use of Oxymetazoline 0.1% Ophthalmic Solution for Acquired Blepharoptosis: A Systematic Review.
Newland Mary, Eberly Hänel, Ma Cheng et al. · Laryngoscope · 2025
PMID: 39172003Meta-AnalysisFull text (PMC)
Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis.
Liu Fei, Zhou Qiujun, Wang Hui et al. · J Cosmet Dermatol · 2023
PMID: 37128814Meta-Analysis
Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.
Neighbors C L, Salvador C Fernandez, Zhu B et al. · J Laryngol Otol · 2022
PMID: 34702392Meta-Analysis
The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial.
Shoji Marissa K, Markatia Zahra, Ameli Kambiz et al. · J Plast Reconstr Aesthet Surg · 2023
PMID: 36996503RCT
A randomized controlled trial on the effects of oxymetazoline nasal spray after dacryocystorhinostomy among adult patients.
Sosuan George Michael N, Ranche Felice Katrina T, Lagunzad John Kenneth D · BMC Res Notes · 2020
PMID: 32357900RCTFull text (PMC)
Topical Oxymetazoline for Fecal Incontinence in Patients with Spinal Cord Injury: A Double-Blind Randomized Controlled Crossover Study.
Barak Nir, Gecse Krisztina B, Takács István · Dis Colon Rectum · 2019
PMID: 30451757RCT
Anesthetic Efficacy of Intranasal 3% Tetracaine plus 0.05% Oxymetazoline (Kovanaze) in Maxillary Teeth.
Capetillo Jeremy, Drum Melissa, Reader Al et al. · J Endod · 2019
PMID: 30803532RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Oxymetazoline (substance)
SNOMED CT
387158001
UMLS CUI
C0030071
RxNorm CUI
7812

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.